Pharming Group N.V./€PHARM
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Pharming Group N.V.
Pharming Group N.V. is a biotechnology company specializing in the development, production, and commercialization of human therapeutic proteins to treat rare diseases. Its core product, Ruconest, is a recombinant human C1 esterase inhibitor used for the treatment of angioedema attacks in patients with hereditary angioedema. Founded in 1988, the company operates primarily from its headquarters in Leiden, Netherlands. Pharming employs proprietary protein-expression technology in the production of these therapeutic proteins, which enables efficient and scalable production processes. The company’s strategic focus on rare diseases and its unique technology platform position it to address unmet medical needs, providing a competitive edge in the biopharmaceutical market.
Ticker
€PHARM
Sector
Primary listing
AEX
Industry
Biotechnology
Headquarters
Employees
404
ISIN
NL0010391025
Website
PHARM Metrics
BasicAdvanced
€606M
-
-€0.02
0.44
-
Price and volume
Market cap
€606M
Beta
0.44
52-week high
€1.10
52-week low
€0.65
Average daily volume
11M
Financial strength
Current ratio
2.761
Quick ratio
1.996
Long term debt to equity
51.259
Total debt to equity
55.341
Interest coverage (TTM)
1.10%
Profitability
EBITDA (TTM)
14.375
Gross margin (TTM)
88.98%
Net profit margin (TTM)
-4.40%
Operating margin (TTM)
4.20%
Effective tax rate (TTM)
-290.62%
Revenue per employee (TTM)
€669,890
Management effectiveness
Return on assets (TTM)
1.99%
Return on equity (TTM)
-6.78%
Valuation
Price to revenue (TTM)
2.201
Price to book
2.77
Price to tangible book (TTM)
7.89
Price to free cash flow (TTM)
138.939
Free cash flow yield (TTM)
0.72%
Free cash flow per share (TTM)
0.64%
Growth
Revenue change (TTM)
24.13%
Earnings per share change (TTM)
30.18%
3-year revenue growth (CAGR)
16.67%
10-year revenue growth (CAGR)
29.99%
3-year earnings per share growth (CAGR)
10.95%
10-year earnings per share growth (CAGR)
-0.95%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Pharming Group N.V. stock?
Pharming Group N.V. (PHARM) has a market cap of €606M as of July 02, 2025.
What is the P/E ratio for Pharming Group N.V. stock?
The price to earnings (P/E) ratio for Pharming Group N.V. (PHARM) stock is 0 as of July 02, 2025.
Does Pharming Group N.V. stock pay dividends?
No, Pharming Group N.V. (PHARM) stock does not pay dividends to its shareholders as of July 02, 2025.
When is the next Pharming Group N.V. dividend payment date?
Pharming Group N.V. (PHARM) stock does not pay dividends to its shareholders.
What is the beta indicator for Pharming Group N.V.?
Pharming Group N.V. (PHARM) has a beta rating of 0.44. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.